Canada, RSV and Moderna
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
However, even established players have struggled. In its Q3 results, GSK (GSK), the first to receive U.S. approval for an ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.
GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...
New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.
RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback